News Release

Journal Article Highlights HemogloBind & AlbuVoid™ to Study Protein Organization in Red Blood Cells

MONMOUTH JUNCTION, NJ , August 28, 2022 -- Biotech Support Group reports on a recent journal article highlighting the simplicity and efficiency of their Hemoglobin and Albumin depletion sample preparation technology for studying the organization of the red cell proteome by LC-MS. The citation is:

Sae-Lee, Wisath, et al. " The protein organization of a red blood cell ." Cell Reports 40.3 (2022): 111103.

Red blood cells (RBCs) (erythrocytes) are the simplest primary human cells, lacking nuclei and major organelles and instead employing about a thousand proteins to dynamically control cellular function and morphology in response to physiological cues. The study defines a canonical RBC proteome and interactome using quantitative mass spectrometry (LC-MS) and machine learning. For this, the investigation analyzed and compared protein and RNA abundances (from MS and RNA-seq data) from RBCs, RBC precursor cells, other blood cell types (including WBCs, platelets, and reticulocytes) and plasma, with the derived likelihood score based solely on these measurements. The article states for red cell preparation, “For hemolysate preparations, remnant white ghosts were removed by centrifugation at 21,000 ×g for 40 min at 4°C, and the supernatant treated with HemogloBind (Biotech Support Group) in order to bind and remove free Hgb.” For plasma preparation, “Plasma was centrifuged at 5,000 x g for 15 mins at 4°C, and only the top part of supernatant was collected. The supernatant was treated with AlbuVoid (Biotech Support Group) to reduce the presence of serum albumin (HSA).” Taken together, the study provides an in-depth view of the global protein organization of human RBCs and serves as a comprehensive resource for future research. 

“It is very rewarding to see that two of our products – HemogloBind™ and AlbuVoid™ were used in this comprehensive study of the red cell proteome. It also demonstrates how we supply products that work through different separations strategies: a direct binding strategy as in HemogloBind™, but also an inverse negative selection strategy, whereby the high abundance protein is voided out; the strategy used with AlbuVoid™” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

For more information on the BSG complete line of Albumin & IgG Removal products , visit: https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

For more information on HemogloBind™, go to: HemogloBind™- Engineered for Hemoglobin Removal and Capture (biotechsupportgroup.com)

For more information on the BSG complete line of Hemoglobin Removal products , visit: Hemoglobin Removal: Overcome Interference (biotechsupportgroup.com)

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, Contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com